Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Hum Gene Ther. 2019 Nov;30(11):1349-1360. doi: 10.1089/hum.2019.021. Epub 2019 Oct 25.
Safe delivery of CRISPR/Cas endonucleases remains one of the major barriers to the widespread application of genome editing. We previously reported the utility of adeno-associated virus (AAV)-mediated CRISPR/Cas genome editing in the retina; however, with this type of viral delivery system, active endonucleases will remain in the retina for an extended period, making genotoxicity a significant consideration in clinical applications. To address this issue, we have designed a self-destructing "kamikaze" CRISPR/Cas system that disrupts the Cas enzyme itself following expression. Four guide RNAs (sgRNAs) were initially designed to target Cas9 (SpCas9) and after validation, the selected sgRNAs were cloned into a dual AAV vector. One construct was used to deliver SpCas9 and the other delivered sgRNAs directed against SpCas9 and the target locus (yellow fluorescent protein [YFP]), in the presence of mCherry. Both constructs were packaged into AAV2 vectors and intravitreally administered in C57BL/6 and transgenic mice. After 8 weeks, the expression of SpCas9 and the efficacy of gene disruption were quantified. A reduction of SpCas9 mRNA was found in retinas treated with AAV2-mediated YFP/SpCas9 targeting CRISPR/Cas compared with those treated with YFP targeting CRISPR/Cas alone. We also show that AAV2-mediated delivery of YFP/SpCas9 targeting CRISPR/Cas significantly reduced the number of YFP fluorescent cells among mCherry-expressing cells (∼85.5% reduction compared with LacZ/SpCas9 targeting CRISPR/Cas) in the transfected retina of transgenic mice. In conclusion, our data suggest that a self-destructive "kamikaze" CRISPR/Cas system can be used as a robust tool for genome editing in the retina, without compromising on-target efficiency.
CRISPR/Cas 内切酶的安全递送仍然是基因组编辑广泛应用的主要障碍之一。我们之前报道了腺相关病毒 (AAV) 介导的 CRISPR/Cas 基因组编辑在视网膜中的应用;然而,使用这种类型的病毒递送系统,活性内切酶将在视网膜中持续存在很长时间,使得基因毒性成为临床应用中的一个重要考虑因素。为了解决这个问题,我们设计了一种自毁的“神风”CRISPR/Cas 系统,在表达后会破坏 Cas 酶本身。最初设计了四个向导 RNA (sgRNA) 来靶向 Cas9 (SpCas9),经过验证后,选定的 sgRNA 被克隆到双 AAV 载体中。一个构建体用于递送 SpCas9,另一个构建体在 mCherry 的存在下递送靶向 SpCas9 和靶标 (黄色荧光蛋白 [YFP]) 的 sgRNA。这两个构建体都被包装到 AAV2 载体中,并通过玻璃体内注射给药于 C57BL/6 和转基因小鼠。8 周后,定量检测 SpCas9 的表达和基因敲除的效果。与单独用 YFP 靶向 CRISPR/Cas 处理的视网膜相比,用 AAV2 介导的 YFP/SpCas9 靶向 CRISPR/Cas 处理的视网膜中 SpCas9 mRNA 减少。我们还表明,AAV2 介导的 YFP/SpCas9 靶向 CRISPR/Cas 的递送显著减少了 mCherry 表达细胞中 YFP 荧光细胞的数量(与 LacZ/SpCas9 靶向 CRISPR/Cas 相比,减少了约 85.5%)在转染的转基因小鼠视网膜中。总之,我们的数据表明,自毁的“神风”CRISPR/Cas 系统可以作为一种强大的基因组编辑工具,用于视网膜,而不会影响靶点效率。